HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Involvement of neuropeptide Y in the acute, chronic and withdrawal responses of morphine in nociception in neuropathic rats: behavioral and neuroanatomical correlates.

Abstract
Although morphine is a potent antinociceptive agent, its chronic use developed tolerance in neuropathic pain (NP). Furthermore, opioid antagonist naloxone attenuated the antinociceptive effect of neuropeptide Y (NPY). The present study investigated the role of NPY and NPY Y1/Y5 receptors in acute and chronic actions of morphine in neuropathic rats using thermal paw withdrawal test and immunocytochemistry. In acute study, intracerebroventricular (icv) administration of morphine, NPY or NPY Y1/Y5 receptors agonist [Leu(31),Pro(34)]-NPY produced antinociception, whereas selective NPY Y1 receptors antagonist BIBP3226 caused hyperalgesia. While NPY or [Leu(31),Pro(34)]-NPY potentiated, BIBP3226 attenuated morphine induced antinociception. Chronic icv infusion of morphine via osmotic minipumps developed tolerance to its antinociceptive effect, and produced hyperalgesia following withdrawal. However, co-administration of NPY or [Leu(31),Pro(34)]-NPY prevented the development of tolerance and withdrawal hyperalgesia. Sciatic nerve ligation resulted in significant increase in the NPY-immunoreactive (NPY-ir) fibers in ventrolateral periaqueductal gray (VLPAG) and locus coeruleus (LC); fibers in the dorsal part of dorsal raphe nucleus (DRD) did not respond. While chronic morphine treatment significantly reduced NPY-ir fibers in VLPAG and DRD, morphine withdrawal triggered significant augmentation in NPY-immunoreactivity in the VLPAG. NPY-immunoreactivity profile of LC remained unchanged in all the morphine treatment conditions. Furthermore, removal of sciatic nerve ligation reversed the effects of NP, increased pain threshold and restored NPY-ir fiber population in VLPAG. NPY, perhaps acting via Y1/Y5 receptors, might profoundly influence the processing of NP information and interact with the endogenous opioid system primarily within the framework of the VLPAG.
AuthorsManoj A Upadhya, Manoj P Dandekar, Dadasaheb M Kokare, Praful S Singru, Nishikant K Subhedar
JournalNeuropeptides (Neuropeptides) Vol. 43 Issue 4 Pg. 303-14 (Aug 2009) ISSN: 1532-2785 [Electronic] Netherlands
PMID19556004 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Analgesics, Opioid
  • BIBP 3226
  • Neuropeptide Y
  • Receptors, Neuropeptide Y
  • Morphine
  • Arginine
Topics
  • Analgesics, Opioid (therapeutic use)
  • Animals
  • Arginine (analogs & derivatives, metabolism)
  • Behavior, Animal (physiology)
  • Drug Tolerance
  • Hyperalgesia (drug therapy, physiopathology)
  • Male
  • Morphine (therapeutic use)
  • Neuropeptide Y (chemistry, metabolism)
  • Pain Measurement
  • Peripheral Nervous System Diseases (pathology, physiopathology)
  • Random Allocation
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Neuropeptide Y (agonists, antagonists & inhibitors, metabolism)
  • Sciatic Nerve (pathology, physiopathology)
  • Substance Withdrawal Syndrome (physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: